Last reviewed · How we verify
PRRT with 177Lu-DOTATATE — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
PRRT with 177Lu-DOTATATE (PRRT with 177Lu-DOTATATE) — Institut Claudius Regaud.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| PRRT with 177Lu-DOTATATE TARGET | PRRT with 177Lu-DOTATATE | Institut Claudius Regaud | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- PRRT with 177Lu-DOTATATE CI watch — RSS
- PRRT with 177Lu-DOTATATE CI watch — Atom
- PRRT with 177Lu-DOTATATE CI watch — JSON
- PRRT with 177Lu-DOTATATE alone — RSS
Cite this brief
Drug Landscape (2026). PRRT with 177Lu-DOTATATE — Competitive Intelligence Brief. https://druglandscape.com/ci/prrt-with-177lu-dotatate. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing